Shopping Cart
Remove All
Your shopping cart is currently empty
Iniparib (BSI-201) (BSI-201) , a PARP1 inhibitor, exhibits potency in triple-negative breast Y (TNBC).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $46 | In Stock | In Stock | |
| 10 mg | $70 | In Stock | In Stock | |
| 25 mg | $128 | In Stock | In Stock | |
| 50 mg | $241 | In Stock | In Stock | |
| 100 mg | $378 | In Stock | In Stock | |
| 200 mg | $600 | In Stock | In Stock | |
| 500 mg | $959 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $50 | In Stock | In Stock |
| Description | Iniparib (BSI-201) (BSI-201) , a PARP1 inhibitor, exhibits potency in triple-negative breast Y (TNBC). |
| In vivo | In 855-2 cells, the combination of BSI-201 (120 μM) and buthionine sulfoximine induced cell death up to 95%, which was similar to the effect on other human tumor cells. In E-ras 20 cells, BSI-201 inhibited cell growth, and its effect was enhanced 20-fold when combined with buthionine sulfoximine. BSI-201 (100 μM) inhibited the repair of ionizing radiation-induced single-strand breaks (SSBs) in human lymphocyte cell lines. |
| Cell Research | Cells are exposed to various concentrations of BSI-201 for 5, and 9 days in the presence or absence of buthionine sulfoxamide (BSO). After treatment, cell proliferation is measured by CellTiter-Glo assay.(Only for Reference) |
| Synonyms | NSC-746045, IND-71677, BSI-201 |
| Molecular Weight | 292.03 |
| Formula | C7H5IN2O3 |
| Cas No. | 160003-66-7 |
| Smiles | N(=O)(=O)C1=CC(C(N)=O)=CC=C1I |
| Relative Density. | 2.055 g/cm3 (Predicted) |
| Color | Red |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 14.6 mg/mL (49.99 mM), Sonication is recommended. DMSO: 85 mg/mL (291.07 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (11.3 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.